EUROPEAN ATHEROSCLEROSIS SOCIETY (EAS)
A non-profit organization, Org nr. 802418-0427

ANNUAL REPORT 2014

OUR MISSION
To advance and exchange knowledge concerning the causes, natural history, treatment and prevention of atherosclerotic disease.

INTRODUCTION
With the dramatic worldwide progression of the pandemic of metabolic diseases including obesity and diabetes, and premature atherosclerosis and cardiovascular disease on the one hand, and with the aging of the European population on the other, atherosclerosis has become a major health concern.

The European Atherosclerosis Society (EAS) seeks to provide a framework for concerted scientific and clinical discussion of new developments in basic research, diagnosis and therapy of atherosclerosis. The EAS is Europe’s resource for expertise in these areas, as well as in inherited disorders of lipid metabolism associated with high cardiovascular risk.

ADVANCING AND EXCHANGING KNOWLEDGE :: EAS Activities in Summary
- Publications: Guidelines and Consensus Position Papers, and in the active support of its official Journal Atherosclerosis.
- The Society organizes an annual Congress for approximately 2000 delegates.
- The Society organizes Advanced Courses for young scientists, highlighting different aspects of basic science and research or clinical prevention, diagnosis and treatment in the field of atherosclerotic vascular disease and its complications.
- The Society’s on-line E-learning platform, EAS Academy, delivers educational material – webcasts, video podcasts, quizzes, articles, technique demonstrations – to the EAS membership and the wider scientific community.
- The Society promotes discussion of topical issues by publication of Featured Commentaries.
- The Society is active in a range of collaborative projects and initiatives with related groups and societies.
CONGRESS IN 2014

The Society’s 82nd Congress, EAS 2014 was held in Madrid, Spain May 31-June 03. The meeting was chaired by Professor Jesus Millan and the chair of the Congress Scientific Programme Committee was Professor Arnold von Eckardstein.

<table>
<thead>
<tr>
<th>Category</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Delegates total</td>
<td>1818</td>
</tr>
<tr>
<td>Countries represented</td>
<td>73</td>
</tr>
<tr>
<td>Abstracts submitted</td>
<td>1183</td>
</tr>
<tr>
<td>Posters Presented</td>
<td>855</td>
</tr>
</tbody>
</table>

A programme of Plenary and Workshop sessions, over four days, was well attended. Presented poster sessions, moderated by distinguished members of EAS, proved once again very popular. Awards were presented to the 24 best posters presented.

The Anitschkow Prize was presented to Professor John J.P. Kastelein, Professor of Medicine at the Department of Vascular Medicine at the Academic Medical Center (AMC) of the University of Amsterdam and Strategic Chair of Genetics of Cardiovascular Disease. Young Investigator Awards were presented to Dr. Ana Catarina Alves Dr James Soh. EAS provided 11 young scientists with grants to cover the cost of their attendance to the Congress.

Selected presentations at the Congress were recorded and made available as webcasts from the EAS Academy. “Highlights” reports were written up by Jane Stock and posted on the Society’s website. The Congress abstracts were published in the Society’s Journal, *Atherosclerosis*.

The Congress marked the 50th Anniversary of the founding of EAS, and this was marked throughout the Congress by special events. Significant figures from the Society’s history were invited to attend a special dinner where they were presented with a plaque to commemorate their services to the Society.

GUIDELINES & RELATED PUBLICATIONS IN 2014

Together with the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH), EAS issued the first set of joint European Guidelines on Prevention of Coronary Artery Disease in 1994. This collaboration has been expanded over the years, and the “Joint European Guidelines on Cardiovascular disease (CVD) Prevention in Clinical Practice” were published in May 2012. In 2014, work commenced on the latest revision and update of these Guidelines. The anticipated publication date is 2016.

The “ESC-EAS Joint guidelines on management of dyslipidemia” were published May 2011 simultaneously in the *European Heart Journal* and the EAS journal *Atherosclerosis*. In the autumn of 2014, work commenced on an update to these Guidelines. The anticipated publication date is 2016.
**CONSENSUS POSITION PAPERS & RELATED PUBLICATIONS IN 2014**

The EAS Consensus Panel is comprised of internationally renowned experts in atherosclerosis and cardiovascular disease, and is co-chaired by Professors John Chapman and Henry Ginsberg. The following Position papers were published during 2014.

<table>
<thead>
<tr>
<th>Publication title</th>
<th>Publication Details</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Consensus Papers</strong></td>
<td></td>
</tr>
</tbody>
</table>
| Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. | European Heart Journal  
DOI: [http://dx.doi.org/10.1093/eurheartj/ehu274](http://dx.doi.org/10.1093/eurheartj/ehu274)  
First published online: 22 July 2014 |
| Management of Statin Intolerant and Statin Resistant Patients                    | Manuscript in preparation                                                            |
| Paediatric Familial Hypercholesterolaemia: optimizing care                       | Manuscript in preparation                                                            |
| What is new in homozygous familial Hypercholesterolaemia?: from genetics to therapy | Manuscript in preparation                                                            |
| **Handbooks for Clinicians**                                                     |                                                                                     |
| A Handbook for Clinicians. Triglyceride-rich Lipoproteins and HDL in Cardiometabolic Disease | Application for iPad published June 2014  
Application for android phone published June 2014  

The coordination and production of the Consensus papers is handled on behalf of the Society by Sherborne-Gibbs, a UK-based medical publishing company. Each initiative is multi-sponsored, funded by project-specific educational grants from pharmaceutical companies, paid to the Society.
**JOURNAL ATHEROSCLEROSIS IN 2014**

Professor Steve Humphries, Editor in Chief, Reviews Editor - Arnold von Eckardstein (Zurich), Supplements Editor - Alberico Catapano (Milan), Editorial Assistant - Sarah Leigh (London).

- Number of Articles submitted: 1,437*
- Number of articles processed: 1,428*
- Number of articles accepted: 335**
- Rejection Rate: 72%

*not all of the articles submitted in 2014 were processed in 2014 (e.g. those received very late in the year may still be undergoing peer-review).

**relates to the processed articles, not necessarily (all) the submitted articles.

The 2014 Impact Factor will relate to articles published in 2012 and 2013. The figures below therefore relate to publishing years 2012-13 and citation year 2014.

- 86.4% of 2012-13 Articles were cited at least once in 2014
- 95.5% of 2012-13 Reviews were cited at least once in 2014
- Total number of Articles/Reviews published in 2012-13: 882
- Total number of 2014 citations to these (2012-13) papers: 3,297
- Average 3.73 citations per paper***
- Average no. Article downloads per month: 66,119 per month in 2014
  (= institutional downloads from ScienceDirect)
- Impact factor: the 2014 IF is expected in spring/early summer.
- 2013 IF is 3.971 (the journal is ranked 15th out of 65 journals in its category, Peripheral and Vascular Disease)

***These figures are from Scopus, and may not be the final citation counts for 2014: more may be added.

The Editorial team write a monthly newsletter to highlight selected articles published in the journal. This is sent via email to all Society members.

The Editorial team held an author and reviewer workshop at EAS 2014 Madrid.
EAS ADVANCED COURSES IN 2014

With these Courses, the Society aims to promote education and training in the prevention and care of atherosclerosis and its clinical manifestations, and equally in basic science, in the atherosclerosis field. The programme of Courses is developed by the Society’s Educational Activities Committee, chaired by Prof Lale Tokgozoglu.

These courses each highlight a different aspect of basic science and research or clinical prevention, diagnosis and treatment in the field of atherosclerotic vascular disease and its complications.

The courses are run by recognized experts and distinguished specialists in the relevant research or clinical area, and are held in established centers of excellence throughout Europe.

- **EAS Advanced Course VIII**  
  *Clinical Excellence in Cardiovascular Prevention and Lipidology*  
  Milan, Italy, April 29-30, 2014  
  - In total 25 doctors from 16 different countries attended this EBAC accredited course  
  - Course Organizer  
  - Professor Alberico L. Catapano, University of Milan, Italy  
  - Course Faculty  
  - Professor Olov Wiklund, Sahlgrenska Academy at the University of Gothenburg, Sweden  
  - Professor Petri Kovanen, Biomedicum, Helsinki, Finland  
  - Professor Lale Tokgozoglu, Hacettepe University, Ankara, Turkey  
  - Professor Danilo Norata, University of Milan, Italy  
  - Dr Fabio Pellegatta, University of Milan, Italy  
  - Dr Liliana Grigore, University of Milan, Italy  
  - Professor Sebastiano Calandra, University of Modena & Reggio Emilia, Modena, Italy

- **EAS Advanced Course IX**  
  *Human Genetics of Dyslipidemia*  
  Sahlgrenska Hospital, Gothenburg, Sweden, December 02-04, 2014  
  - In total 26 doctors from 14 different countries attended this EBAC accredited course  
  - Course Organizers  
  - Prof. Stefano Romeo and Prof. Olov Wiklund, University of Gothenburg, Sweden  
  - Course Faculty  
  - Knut Erik Berg, University of Oslo, Norway  
  - Maria Antonella Burza, University of Gothenburg, Sweden  
  - Erik Ingelsson, Karolinska Institutet, Stockholm, Sweden  
  - Stefano Romeo, University of Gothenburg, Sweden  
  - Anne Tybjaerg-Hansen, Copenhagen, Denmark  
  - Luigi Palla, London School of Hygiene and Tropical Medicine, UK  
  - Marju Orho Melander, University of Lund, Sweden  
  - Olle Melander, University of Lund, Sweden  
  - Ruth Loos, Mount Sinai, New York, US

Other EAS-endorsed Courses were held in Athens, Istanbul, Dubai, and Busan.
ONLINE EDUCATION IN 2014 :: EAS Academy

The Society’s educational platform, EAS Academy, was launched in 2013 and continues to develop, with newly recorded material added from the courses and Congress that took place in 2014.

Content formats:

- Webcasts and video podcasts
- Learning quizzes
- Guidelines and Consensus papers
- Videos of clinical techniques

Content by Topic

<table>
<thead>
<tr>
<th>Topic</th>
<th>Items on the Academy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arterial wall &amp; AS</td>
<td>54</td>
</tr>
<tr>
<td>Lipids, lipoproteins and metabolism</td>
<td>93</td>
</tr>
<tr>
<td>Risk factors</td>
<td>19</td>
</tr>
<tr>
<td>Epidemiology and prevention</td>
<td>46</td>
</tr>
<tr>
<td>Diagnosis and imaging in atherosclerosis</td>
<td>16</td>
</tr>
<tr>
<td>Therapy</td>
<td>144</td>
</tr>
<tr>
<td>Genetics</td>
<td>27</td>
</tr>
</tbody>
</table>

EAS Academy

- can be accessed via computers and mobile devices via “Talks on the Go”® App
- is regularly updated with new material
- has two different classes of content
  - **Premium** content for EAS members & paying subscribers only
  - **Regular** content - Accessible for all

The company engaged to manage the Academy is Multiwebcast, based in Canada, with an office in France.
ONLINE EDUCATION IN 2014 :: EAS Certificate of Clinical Excellence in Lipidology

This initiative has been created by the Committee for Educational Activities, led by Prof Lale Tokgozoglu. It is an accredited programme combining courses and online learning to provide a unique, comprehensive and accredited training for clinicians.

**Online part:** A structured, modular curriculum to be created using the Academy platform. Each module to consist of learning objectives and a recorded presentation or written paper and multiple choice questions. To complete a module, the participant must achieve a pass score (80%). Modules must be completed in a set order. The core curriculum of compulsory modules ensures all essential topics are covered. Further, Supplementary modules can be selected in participant’s areas of interest. The multiple-choice questions have been set by EAS. The modules will carry EBAC accreditation.

**Live part:** Each participant in the programme must take part in an EAS Advanced Course. Points may also be achieved by attending EAS Congress.

Participants have one calendar year to complete the programme. Certification is valid for a period of three years, then must be repeated. Participants must complete regular updates throughout the three-year period.

The planning of and work on the Programme started in 2014, and the anticipated launch of the Programme is Q1 2015.

The Programme is supported by unrestricted educational grants from several pharmaceutical industry supporters.
COLLABORATIONS IN 2014

Joint sessions at Congress
EAS continues to maintain good relations with other international and European organizations. The following exchanges of sessions at Congress continue:

- The International Chair on Cardiometabolic Risk (ICCR): Joint sessions at the annual EAS Congress
- European Society of Cardiology (ESC): Joint sessions at both ESC and EAS Congress

EFLM
The European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) and EAS have set up a working group to develop a consensus on recommendations for lipid and lipoprotein determination and measurement in laboratories. Plans are ongoing to arrange meetings of a panel of experts in 2015.

Agreed issues to be addressed:

- Reporting of lab results: there is no standardization or consensus for the reporting of lipid measurements. Notably reference or ideal values are not reported uniformly.
- Pre-analytical issues are not uniformly defined (fasting or non-fasting)
- Alternative measures such as non-HDL-C, apoA-I and apoB, LDL-P, and Lp(a) to be commented
- The inaccuracy and lack of accordance of homogenous HDL and LDL assays as well as the Friedewald formula especially in dyslipidaemic samples

The goal of the meetings is the publication of a consensus position paper on the above issues.

This initiative is supported by unrestricted educational grants from several pharmaceutical industry supporters to both EAS and EFLM.

Familial Hypercholesterolaemia Studies Collaboration (FHSC)
During 2014 EAS launched a major new initiative to tackle the unmet need of patients with Familial Hypercholesterolaemia (FH). The EAS FH Studies Collaboration (FHSC) is a global initiative led by Prof Kausik Ray (London, UK) and an international steering committee.

The mission of EAS FHSC is to empower the medical/global community to seek change in their respective countries or organizations regarding how FH is detected and managed, with a view to promoting early diagnosis and more effective treatment of this condition. The aim of the collaboration is to generate large-scale robust data on how FH is detected, managed and the clinical consequences of current practice on outcomes. The group will work with all stakeholders, including patient’s organizations, to ensure that these state-of-the-art information are utilized to close gaps in knowledge and/or improve clinical practice for FH patients.

Planning, and setting up of the network infrastructure was started in 2014, and will continue into 2015-2016.

Applications for educational grants in support of this Programme from several pharmaceutical industry supporters have been made.

European Lipoprotein Club (ELC)
The ELC currently comprises over 500 scientists from more than 20 countries in Europe and abroad – a worldwide network of basic scientists and clinicians involved in lipoprotein research. Over the past two years, EAS has been a supporter of the ELC’s annual meeting.

During 2014 it was decided to further assist ELC with administrative support. The EAS Office will provide logistical support to the ELC organizing Committee in the practical aspects of running the
meeting, including hosting and maintaining the ELC website, abstract submission processes and meeting registration.

Organisation started in Q4 2014 in planning the ELC 2015 meeting.

**UNIVADIS®**
This activity, initiated during 2014, concerns the dissemination of EAS content via UNIVADIS® (to more than 80 countries worldwide, making it available to more than 2,6M healthcare professionals, of whom 428k are GPs, cardiologists and endocrinologists.

EAS to supply content in the form of review articles recently published in the Society’s journal *Atherosclerosis*. These will be translated into a number of different languages, and accompanied by expert commentaries in the form of short video introductions. The selection of the articles is to be done by the Journal Editor in Chief. EAS has engaged a coordinator to manage the selection of experts in the appropriate field and the recording of the accompanying introductions.

The Programme is supported by an educational grant from a pharmaceutical industry supporter.

**Alliance for Biomedical research in Europe (BioMed Alliance)**
EAS is a member of the BioMed Alliance - an initiative representing 21 leading research-oriented medical societies that include more than 200.000 researchers across Europe.

The mission of the BioMed Alliance is to advance and strengthen biomedical research, in particular translational research, which is crucial for innovation. The objectives of the BioMed Alliance are to facilitate and improve biomedical research, develop a framework for better training and mobility of young researchers and improve public understanding of medical science in Europe.

During 2014 EAS has participated in the activities of the Alliance through representation at Alliance Board meetings and participation in the preparation of a written Code of Conduct (currently ongoing).
CORPORATE PARTNERSHIPS IN 2014

EAS has a Corporate Partnership programme
- to foster working relationships with industry
- to identify common goals and
- to design interactive, mutual strategies to achieve them

Support from our corporate partners allows EAS to organize and implement the educational initiatives which are its core mission. The Society acknowledges support from the following partners.

<table>
<thead>
<tr>
<th>Corporate Partner</th>
<th>Activities and initiatives supported</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sanofi-Regeneron</td>
<td>• Silver level partnership&lt;br&gt;• Congress sponsor&lt;br&gt;• Statin intolerance Consensus sponsor&lt;br&gt;• Advanced Courses&lt;br&gt;• Clinicians Handbook Apps</td>
</tr>
<tr>
<td>BASF/Danone/Raisio/Unilever</td>
<td>• Silver level partnership&lt;br&gt;• Plant sterol consensus sponsor&lt;br&gt;• Congress sponsor</td>
</tr>
<tr>
<td>Aegerion</td>
<td>• Bronze level partner&lt;br&gt;• Congress sponsor&lt;br&gt;• Bronze level partner&lt;br&gt;• Congress sponsor&lt;br&gt;• Statin intolerance Consensus sponsor&lt;br&gt;• Certificate of Excellence in Lipidology programme supporter</td>
</tr>
<tr>
<td>Amgen</td>
<td>• Bronze level partner&lt;br&gt;• Congress sponsor (grant)&lt;br&gt;• Statin intolerance Consensus sponsor&lt;br&gt;• Clinicians Handbook Apps</td>
</tr>
<tr>
<td>AstraZeneca</td>
<td>• Bronze level partner&lt;br&gt;• Congress sponsor&lt;br&gt;• Activities with European Federation of Laboratory Medicine (EFLM)&lt;br&gt;• Advanced Courses&lt;br&gt;• Statin intolerance Consensus sponsor&lt;br&gt;• Certificate of Excellence in Lipidology programme supporter</td>
</tr>
<tr>
<td>Kowa</td>
<td>• Bronze level partner&lt;br&gt;• Congress sponsor&lt;br&gt;• Congress sponsor&lt;br&gt;• Activities with European Federation of Laboratory Medicine (EFLM)&lt;br&gt;• Advanced Courses&lt;br&gt;• Statin intolerance Consensus sponsor&lt;br&gt;• Certificate of Excellence in Lipidology programme supporter</td>
</tr>
<tr>
<td>Merck</td>
<td>• Bronze level partner&lt;br&gt;• Congress sponsor&lt;br&gt;• Certificate of Excellence in Lipidology programme supporter</td>
</tr>
<tr>
<td>Pfizer</td>
<td>• Bronze level partner&lt;br&gt;• Congress sponsor&lt;br&gt;• Statin Intolerance Consensus sponsor&lt;br&gt;• Congress sponsor</td>
</tr>
<tr>
<td>Eli Lilly</td>
<td>• Bronze level partner&lt;br&gt;• Statin Intolerance Consensus sponsor&lt;br&gt;• Congress sponsor</td>
</tr>
<tr>
<td>Chiesi</td>
<td>• Bronze level partner&lt;br&gt;• Congress sponsor</td>
</tr>
</tbody>
</table>

We are also grateful for support from non-partners, including:

<table>
<thead>
<tr>
<th>Company</th>
<th>Activities and initiatives supported</th>
</tr>
</thead>
<tbody>
<tr>
<td>Esperion</td>
<td>• Statin intolerance Consensus sponsor</td>
</tr>
<tr>
<td>Denka Seiken</td>
<td>• Activities with European Federation of Laboratory Medicine (EFLM)</td>
</tr>
</tbody>
</table>
SCIENTIFIC COMMENTARY

Regular (8 issues per year) topical commentaries on recent developments in the field are commissioned by EAS and written by freelance journalist and medical writer, Jane Stock. These are published on the EAS website and sent as an email newsletter to EAS members.

MEMBERSHIP

During the Society’s General Members Assembly 2014, a proposal to restructure the membership categories for the Society was approved. This allows national atherosclerosis Societies, as well as other societies and groups, to become members of EAS – affording to their members selected EAS membership benefits, and creating new opportunities for EAS and national atherosclerosis Societies to collaborate on initiatives and activities. To date the following have become members of EAS

European Lipoprotein Club
Turkish Society of Cardiology, Working Group on Atherosclerosis
Italian Atherosclerosis Society
Hellenic Society of Atherosclerosis

Several other societies are in the process of taking up membership.
At the close of 2014 EAS had 1590 subscribed members.

ONGOING ACTIVITIES IN 2014

Administrative:

- The Society’s financial accounts are monitored by auditor is Kristina Ringvall, of Grant Thornton.
- Legal issues are referred to Rolf Karlsson, of the law firm Delphi.

Agreements: The contract for PCO of EAS Congress 2017-2018 was put out to tender during 2014. Agreement and final decision on the selected PCO is yet to be reached.

Consultancy: Consultant Leonhard Loew continues to advise on the Society’s processes and operations, with recommendations for the Society’s strategic development.

Annual General Meeting: The Society’s Annual General Assembly was held during the annual Congress in Madrid, June 02 2014. The Society’s Constitution was amended.

Future Congress planning:

During 2014, bids to host EAS Congress 2017 were received from the cities of Athens, Helsinki, Istanbul and Prague. Visits to all four cities will be made by Professor Catapano and Carmel Hayes for the Executive Committee in January 2015.

During 2014, the focus of the Congress activities was the planning of the 83rd EAS Congress in Glasgow, UK, 2015, and preparation activities for the 84th EAS Congress in Innsbruck, Austria, 2016.

Member administration & website: The Society’s website and member database is currently hosted and maintained by a company, Triggerfish, based in Stockholm, Sweden. The requirements of the system, in both function and capacity, have reached the limit at which Triggerfish can support it.

During 2014, having sought offers from a range of suppliers of member-management systems, the decision has been taken to move the database to a new supplier, YourMembership, based in the USA.

The move will take place during the first half of 2015, and will involve a complete overhaul and redesign of the Society’s website. This work will be handled by the EAS Office team, and will result in more efficient handling of member services and improved integration with external sites from the EAS website.
Representation and promotional activities: During the Congress of the European Society of Cardiology (ESC 2014 Barcelona), members of the Executive Committee met with EAS Corporate Partners to discuss ongoing and future educational initiatives.

The EAS participated in the exhibition at the Congress of the European Society of Cardiology (ESC 2014 Amsterdam; 28 000 delegates from 140 countries) to promote the Society's activities and future Congresses.

MANAGEMENT

The management of the EAS consists of nine Executive Committee members and three Adjunct Committee members. Each member is elected for a term of 4 years. The Executive Committee met face to face on three occasions during 2013: February (Gothenburg), June (Lyon), and October (Madrid).

Officers and Elected Committee members:

- There was no change to the Society leadership during 2014

EAS Executive Committee:

<table>
<thead>
<tr>
<th>Last Name</th>
<th>First Name</th>
<th>Position</th>
<th>Term</th>
</tr>
</thead>
<tbody>
<tr>
<td>Catapano</td>
<td>Alberico</td>
<td>President</td>
<td>January 2013-December 2016</td>
</tr>
<tr>
<td>Wiklund</td>
<td>Olov</td>
<td>Vice President</td>
<td>January 2013-December 2016</td>
</tr>
<tr>
<td>Chapman</td>
<td>John</td>
<td>Past President</td>
<td>January 2013-December 2016</td>
</tr>
<tr>
<td>Kovanen</td>
<td>Petri</td>
<td>Secretary</td>
<td>January 2013-December 2016</td>
</tr>
<tr>
<td>Borén</td>
<td>Jan</td>
<td>Treasurer</td>
<td>January 2014-December 2017</td>
</tr>
<tr>
<td>Dallinga-Thie</td>
<td>Geesje</td>
<td>Member</td>
<td>January 2013-December 2016</td>
</tr>
<tr>
<td>Nordestgaard</td>
<td>Berge</td>
<td>Member</td>
<td>January 2013-December 2016</td>
</tr>
<tr>
<td>von Eckardstein</td>
<td>Arnold</td>
<td>Member</td>
<td>January 2012-December 2015</td>
</tr>
<tr>
<td>Vrablik</td>
<td>Michal</td>
<td>Member</td>
<td>January 2013-December 2016</td>
</tr>
</tbody>
</table>

Sub-Committee Chairs

<table>
<thead>
<tr>
<th>Last Name</th>
<th>First Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Taskinen</td>
<td>Marja-Riitta</td>
</tr>
<tr>
<td>Tokgozoglu</td>
<td>Lale</td>
</tr>
<tr>
<td>Kovanen</td>
<td>Petri</td>
</tr>
<tr>
<td>Wiklund</td>
<td>Olov</td>
</tr>
<tr>
<td>Catapano</td>
<td>Alberico</td>
</tr>
</tbody>
</table>

Employees

During 2014 the Society had three employees.

- Dr. Carmel Hayes, Administrative Executive
- Josefine Harbrecht, Administratror
- Mikaela Askeroth-Grundén, Administrator

The EAS Administrative Office is located in Gothenburg, Sweden.

Committee Meetings

During 2014 the following face to face meetings were held:

- 3 x Executive Committee
- 3 x Congress Committee
- 2 x Educational Activities Committee
- 2 x President’s visit to EAS Offices
- EAS leadership meetings with Corporate partners at both EAS 2014 Madrid and ESC 2014 Barcelona